Genzyme

In separate agreements, Roche has obtained a worldwide sub-license from Genzyme to develop the EGFR assay, and will collaborate with OSI Pharmaceuticals to develop the companion diagnostic.

Clearance from the FTC removes one hurdle for the $925 million deal, which is expected to close on or about Dec. 1.

Part of the funds from the offering will be used to pay for LabCorp's $925 million acquisition of Genzyme Genetics.

This week executives from several firms in the molecular research tools and molecular diagnostics fields made their pitch to investors at the annual UBS Global Life Sciences Conference.

Genzyme's genetics division, when combined with the Monogram Biosciences assets that it acquired last year, should help bolster LabCorp's position as a provider of personalized medicine products for cancer.

LabCorp will purchase the Genetics segment in its entirety, including all testing services, technology, intellectual property rights, and its nine testing laboratories and offer employment to all of its 1,900 employees.

Movers & Shakers

Premium

Ian Walker, Ian Abercrombie, Stefan Gruenwald

Movers & Shakers

Premium

Andreas Menrad, Jurgen Wahl, Ranier Kroell

As part of the deal, which is expected to give Targeted Genetics enough cash to continue operations through 2010, the firm licensed back the technology and IP for certain drug-development efforts, including its RNAi-based Huntington’s disease program.

Massachusetts Biotech-Labor Dispute, Lexington (Mass.) Technology Park, Pfizer-Wyeth Merger

Pages

An analysis of UK Biobank data finds hemochromatosis to be more prevalent than thought, according to the BBC.

An analysis finds that female biomedical researchers receive fewer prizes than male ones, and when they do win prizes, they are less prestigious.

In Nature this week: improved genomic analysis using a graph genome reference, tumor mutational burden could predict clinical response to immune checkpoint inhibitors, and more.

Federal researchers tell the Los Angeles Times that the shutdown is causing missed research opportunities as they try to keep their experiments going.